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Gordon Holmes syndrome (GHS) is a rare Mendelian neurodegenerative disorder characterized by ataxia and
hypogonadism. Recently, it was suggested that disordered ubiquitination underlies GHS though the discovery
of exome mutations in the E3 ligase RNF216 and deubiquitinase OTUD4. We performed exome sequencing in a
familywith twoof threesiblingsafflictedwithataxiaandhypogonadism andidentifiedahomozygousmutation in
STUB1 (NM_005861) c.737CT, p.Thr246Met, a gene that encodes the protein CHIP (C-terminus of HSC70-inter-
actingprotein).CHIPplays acentral role in regulatingproteinquality control, inpart through itsability to function
as an E3 ligase. Loss of CHIP function has long been associated with protein misfolding and aggregation in sev-
eral genetic mouse models of neurodegenerative disorders; however, a role for CHIP in human neurological dis-
ease has yet to be identified. Introduction of the Thr246Met mutation into CHIP results in a loss of ubiquitin ligase
activity measured directly using recombinant proteins as well as in cell culture models. Loss of CHIP function in
mice resulted in behavioral and reproductive impairments that mimic human ataxia and hypogonadism. We con-
clude that GHS can be caused by a loss-of-function mutation in CHIP. Our findings further highlight the role of
disordered ubiquitination and protein quality control in the pathogenesis of neurodegenerative disease and
demonstrate the utility of combining whole-exome sequencing with molecular analyses and animal models to
define causal disease polymorphisms.
INTRODUCTION
Gordon Holmes syndrome (GHS [MIM 212840]) is a rare neuro-
degenerative disorder characterized by ataxia with hypogonad-
ism (1). Despite almost 100 years of clinical recognition, there
is still little understanding of the pathophysiological mechan-
isms or underlying genetic causes of GHS. Recently, mutations
in the E3 ligase RNF216 and deubiquitinase OTUD4 were asso-
ciated with GHS in multiple non-Asian families (2), suggesting
that disordered ubiquitination plays an essential role in the
pathophysiology of ataxia and hypogonadism.
Protein ubiquitination is primarily regulated through E3
ligases that construct covalently linked polyubiquitin chains
on protein substrates, subsequently resulting in the targeting of
ubiquitinated proteins for degradation through the 26S prote-
asome. C-terminus of HSC70-interacting protein (CHIP) is a
35-kDa protein that functions as both a molecular cochaperone,
autonomous chaperone and ubiquitin E3 ligase (3–6). In cooper-
ation with heat shock chaperone proteins, including HSC70,
HSP70 and HSP90, CHIP plays a crucial role in recognizing
and modulating the degradation of numerous chaperone-bound
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proteins. In genetic mouse models of neurodegenerative disease,
the loss of CHIP function is associated with the misfolding and
aggregation of several proteins (such as expanded polygluta-
mine tracts, hyperphosphorylated Tau and oligomeric forms of
a-synuclein), all of which are thought to be associated with mul-
tiple neurodegenerative disorders such as Spinocerebellar
ataxia, Alzheimer’s disease and Parkinson’s disease (7–9).
However, mutations in the human STUB1 gene have not been
reported, and information about the physiology of CHIP defi-
ciency in humans is non-existent. Using exome sequencing,
we identified a STUB1 mutation in two patients from a pedigree
that presented with GHS. We demonstrate that the STUB1 muta-
tion leads to a loss in function of CHIP resulting in diminished E3
ligase activity; furthermore, mice lacking the expression of
CHIP phenocopy some aspects of human GHS, supporting a
direct link between CHIP and GHS pathophysiology.
RESULTS
Clinical assessment of two sisters with GHS
We initially observed a pedigree characterized by ataxia with
hypogonadism in two sisters (II-1 and II-2) with an autosomal
recessive inheritance pattern. The initial behavioral and sexual
development of the proband (II-1) appeared normal, but un-
steady gait developed when she was 19 years old, followed by
dysarthria 2 years later and remarkable ataxia (Table 1). Upon
neurological examination, Patient II-1 exhibited horizontal
gaze-evoked nystagmus with no restriction of extraocular move-
ment. Photography and fluoresce angiogram of the ocular fundus
revealed no abnormality (data not shown). Additionally, muscle
tone, power and deep tendon reflexes of the four limbs were
normal without any overt pathology. Neuroelectrophysiological
examination was generally normal, except for decreased ampli-
tude of motor-evoked potential in the bilateral lower limbs.
The younger sister (II-2) also had a similar illness recognized
at 17 years of age with a progressive deterioration of balance and
gait disturbance (Table 1). Over the next 2 years, Patient II-2
developed noticeable hand tremors during activity along with
coarse head tremors. Further examination revealed findings
similar to Patient II-1, in addition to increased tendon reflex
and positive pathological signs in the four limbs, suggesting pyr-
amidal tract lesions. Patients II-1 and II-2 were administered the
mini-mental state examination (MMSE) resulting in normal cog-
nitive scores, whereas the Montreal Cognitive Assessment
(MoCA), which is more sensitive to subtle cognitive defects par-
ticularly in the early stages of disease (10), did reveal cognitive
deficiencies in both sisters (Table 1). Furthermore, patients II-1
and II-2 completed only 4 and 8 years of schooling, respectively.
The neurological phenotype consisting of severe ataxia with se-
lective cognitive impairments is consistent with cerebellar
ataxia. The diagnosis of cerebellar ataxia was confirmed with
MRI brain scans of both sisters that revealed remarkable
atrophy of the cerebellum in both sisters (Fig. 1A).
In addition to the neurological defects, both sisters had poor
sexual organ development. At 22 years of age, Patient II-1 had
still not menstruated, had poor development of secondary
sexual characteristics (Table 1) and hypoplasia of uterus and
ovaries, as revealed via ultrasound analysis (Table 1). Similar
to her elder sister, Patient II-2 did not attained menarche or
any secondary sexual characteristics, presenting with infantile
uterus and ovarian development (Table 1). Along with the lack
of sexual development in both patients, the serum levels of estra-
diol and progesterone were much lower than the normal refer-
ence range, leading to a diagnosis for both patients of
hypogonadotropic hypogonadism (Table 1). In addition to the
low circulating sex hormones and the lack of menses, levels
of the pituitary hormones follicle-stimulating hormone (FSH)
and luteinizing hormone (LH) in both sisters were comparable
to prepubescent levels (Table 1). The nature of the hypogonad-
ism in GHS is still not clear and may derive from either
hypothalamic or pituitary hypogonadotropism (11). Interesting-
ly, a gonadotropin-releasing hormone (GnRH) stimulation test
showed that the pituitaries in both patients were responsive to
a single intravenous dose of GnRH (100 mg) measured by the sti-
mulated release of FSH and LH (Fig. 1B), suggesting that the
primary defect in these sisters may be due to hypothalamic
versus pituitary hypogonadotropism. However, the pituitary re-
sponse to GnRH in other GHS patients is reported to diminish
over time, suggesting that pituitary dysfunction may still be an
issue in these patients (2, 11), making it difficult to pinpoint
the primary lesion of the hypogonadotropism hypogonadism in
GHS. The two patients in this study were referred to a gyneco-
logical endocrinologist, and exogenous estrogen and progestin
supplement therapy was administered in an attempt to construct
an artificial menstrual cycle. After 3 weeks of therapy, their me-
narche came, demonstrating that the lack of reproductive organ
maturity was due to the lack of circulating hormones.
Exome sequencing reveals a mutation in Stub1 associated
with GHS
In an attempt to identify the causative mutation in this family, we
performed whole-exome sequencing of the two affected patients
(II-1, II-2) as well as the unaffected brother (II-3). Using a com-
bination of bioinformatic repositories and functional algorithms,
we developed a strategy to identify causal mutations segregating
with the GHS phenotype (Fig. 2A). After quality control and
coverage criteria were met, we started with a total of 98 255,
96 183, 98 507 SNPs, and 7227, 7046, 7159 insertions or dele-
tions (indels) for II-1, II-2 and II-3, respectively. Since ataxia








Tanner stage II–III II–III
Corpus uterus (mm) 35 × 31 × 25 28 × 20 × 19
Cervix (mm) 23 16
Ovaries (mm) 14 × 9 13 × 10
Hypogonadism
Estradiol (pg/ml) 26 28
Progesterone (ng/ml) 0.31 0.33
FSH (mIU/ml) 6.97 6.25
LH (mIU/ml) 5.95 6.44
FSH, follicle-stimulating hormon; LH, luteinizing hormone.
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Figure 1. Clinical manifestations in patients presenting with ataxia and hypogonadism. (A) MRI scans revealed remarkable cerebellum atrophy of Patients II-1 (left)
and II-2 (right). (B) GnRH stimulation tests measured the response in circulatingFSH and LH serum levels to exogenousGnRH administration (at time ¼ 0) in Patients
II-1 (left) and II-2 (right).
Figure 2. Exome sequencing identifies a p.Thr246Met mutation in the GHS family. (A) Schematic representation of our exome data-filtering approach to identify
mutations with recessive inheritance patterns in the family. (B) Posterior probabilities of IBD ¼ 2 classification. The logarithmic ratio (LOD) of the posterior prob-
abilities of being IBD ¼ 2 versus IBD = 2 are plotted for all classified variant positions on chromosome 16. A disease-causing mutation in the STUB1 gene was iden-
tified in an IBD ¼ 2 region of high posterior probability, indicated by the red arrow. (C) A pedigree of the family indicating the unaffected (open symbols) and affected
(filled symbols) members. Sanger sequencing confirmed the cosegregation of the c.737CT resulting in p.Thr246Met mutation in STUB1 within the family.
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with hypogonadism is a rare disorder but has a clear phenotype,
there was a low likelihood that a causal mutation in our patients
was present in wider, healthy populations. We therefore filtered
for novel variants by comparing our exome data to dbSNP build
132 (12), the 1000 Genomes Project (13), Hapmap (14, 15), YH
project (16), and the National Heart, Lung and Blood Institute
Exome Sequencing Project (17), further refining our target list
to 2000 SNPs and 130 indels (Fig. 2A). Next, we filtered for
a recessive inheritance pattern for variants that were present in
the affected sisters, but not in the unaffected brother, which
reduced the number of candidate variants to six, including
three compound heterozygote variants and three homozygous
variants (Fig. 2A and Supplementary Material, Table S1).
The analysis of chromosomal regions that are identical by
descent (IBD) is a form of homozygosity mapping, a fundamental
tool in linkage analysis of pedigree data. For Mendelian diseases
with a recessive inheritance pattern, affected family members
usually share the genomic segment harboring the causal mutation.
Therefore, variants inside the IBD regions found among the
affected family members are of primary interest and can be
exploited to identify genomic regions consistent with inheritance
of a recessive monogenic disease (18, 19). These regions of inter-
est are indicated by an IBD score of two, signifying the intersec-
tion between paternal and maternal haplotypes (19). Using the
criteria of IBD ¼ 2, we excluded three additional variants, redu-
cing the number of candidate variants to three. Finally, we
carried out functional-impact prediction on protein mutations
by PolyPhen-2 (20), Mutation Taster (20) and SIFT (21). Interest-
ingly, only one homozygous variant predicted an impact on
protein function in this family, STUB1 (NM_005861)
c.737CT, resulting in a p.Thr246Met (T246M) amino acid
change in the corresponding protein commonly known as CHIP
(Fig. 2C). As an additional control, we tested for the STUB1
c.737CT mutation in 500 Chinese control individuals; consist-
ent with our data mining of multiple SNP databases used in our fil-
tering strategy (Fig. 2A), the c.737CT mutation was not
detected in the Chinese control population.
The genetics of cerebellar ataxia has been intensely pursued over
the last decade, identifying over 30 loci that associate with the
disease (22). Therefore, we were not surprised that we did not
detect any STUB1 mutations in an additional cohort of 32
Chinese cerebellar ataxia patients without hypogonadism, suggest-
ing that mutations in STUB1, and the recently described mutations
in RNF216/OTUD4, associate with the distinct pathophysiological
phenotype of cerebellar ataxia with hypogonadism. We also
sequenced the STUB1 gene in a cohort of five GHS patients that
harbor a single heterozygous RNF216 mutation and eight GHS
patients that do not have either RNF216 and OTUD4 mutations
(2); interestingly, we did not identify any mutations in STUB1 in
any of these GHS patients, suggesting that additional genetic
factors likely remain to be identified in other GHS patient popula-
tions. We also performed copy number variations (CNVs) analysis
and did not find any CNV that cosegregated either separately with
the disease phenotype or together with single heterozygous varia-
tions in this family (23), suggesting that gene dosage was not con-
tributing to the GHS phenotype. Taken together, our genetic and
bioinformatics analyses demonstrate the association of the
STUB1 c.737CT mutation with GHS and predict the T246M
in CHIP results in a functional change that directly contributes to
the pathophysiology of cerebellar ataxia and hypogonadism.
The T246M mutation in CHIP abolishes ubiquitin ligase
activity
The identification of the homozygous c.737CT mutation in
sibling GHS subjects and the cosegregation of functional muta-
tion algorithms predicting a strong impact on protein function
suggested that the resulting T246M substitution mutation in
CHIP results in a change in protein function. T246, which is
highly conserved across CHIP homologs, is located within the
U box domain of CHIP (Fig. 3A), the domain responsible for ubi-
quitin ligase activity (5). In addition, T246 is located in the core
of a conversed beta hairpin turn (Fig. 3A) (24), likely contribut-
ing to the high impact scores of the T246M mutation identified in
our functional prediction analysis (Fig. 2A). In addition to the
role that CHIP plays as a ubiquitin ligase, CHIP can also act as
a co-chaperone through its direct interactions with cellular cha-
perones including HSC70, HSP70 and HSP90 via CHIP’s tetra-
tricopeptide repeat (TPR) domain (Fig. 3A) (3–5, 25). Both a
functional TPR and U box domain are required for CHIP’s
ability to directly impact protein quality control and attenuate
the cellular stress response in large part through polyubiquitian-
tion of HSP chaperones (26, 27). Given that the CHIP mutation
identified in our patients resides in the U box domain, we
hypothesized that the T246M substitution would result in a
loss of CHIP’s ubiquitin ligase activity, without affecting
CHIP’s interaction with cellular chaperones though the intact
TPR domain.
To test effect of the T246M substitution on CHIP’s ubiquitin
ligase activity and its ability to bind to chaperones, we first
expressed either wild-type CHIP (CHIP-WT) or CHIP engi-
neered with a methionine substituted for threonine at residue
246 (CHIP-T246M) in COS-7 cells. As expected, both the WT
and T246M proteins immunoprecipitated with exogenous
HSP70 (Fig. 3B and Supplementary Material, Fig. S1A), demon-
strating that CHIP-chaperone interactions are not perturbed by
the T246M substitution. In fact, more CHIP-T246M protein
immunoprecipitated with HSP70 compared with CHIP-WT
(Fig. 3B and Supplementary Material, Fig. S1A). Surprisingly,
the increased interaction between CHIP-T246M and HSP70
did not result in robust HSP70 ubiquitination compared with
CHIP-WT expressing cells (Fig. 3B and Supplementary Mater-
ial, Fig. S1A), indicating that the T246M substitution deleteri-
ously affects CHIP’s ubiquitin ligase activity. We
subsequently tested both the interaction and ubiquitination func-
tion of CHIP-T246M on an endogenously expressed CHIP sub-
strate, HSC70, and again observed an increased interaction
between CHIP-T246M and HSC70 with diminished polyubiqui-
tination (Fig. 3C). Together, these data suggest that the function-
al defect in CHIP-T246M is a loss of ubiquitin ligase activity.
To directly test the impact of the T246M substitution on
CHIP-dependent substrate ubiquitination, we compared the
T246M mutation to previously engineered point mutations of
CHIP. To do this, we used CHIP constructs with mutations
located either in the TPR domain (CHIP-K30A) or the U box
(CHIP-H260Q), which abolish either the interaction with cellu-
lar chaperones, such as HSC70 and HSP70, or the ubiquitin
ligase activity of CHIP, respectively (Fig. 3A), using cell-free
assays comprising purified recombinant proteins. Similar to
the results observed in cell culture models (Fig. 3B and C),
CHIP-T246M failed to polyubiquitinate HSC70 in vitro,
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mimicking the effect of the H260Q (U box) mutant CHIP protein
(Fig. 3D and Supplementary Material, Fig. S2B). To confirm that
the lackof chaperoneubiquitination invitro isdue toa defect in the
U box domain and not due to the inability to bind to the chaperone
substrate, we measured the effect of the CHIP-T246M mutation
CHIP’s intrinsic ability to autoubiquitinate, a phenomenon that
readily occurs in vitro (27). Similar to the H260Q mutation, the
CHIP-T246M mutantdidnotexhibitanyautoubiquitination (Sup-
plementary Material, Fig. S2B), in contrast to CHIP-WT and
CHIP-K30A proteins that both contain functional U boxes
(Fig. 3E), confirming that the T246M mutation abolishes
CHIP’s ubiquitin ligase activity. Taken together, these data
Figure 3. The T246M substitution mutation in CHIP abolishes ubiquitin ligase activity. (A) CHIP comprises three functional domains: TPR, coiled-coil (CC) and U
box. The arrows indicate the location and identity of point mutations used to measure the functional parameters of CHIP (top). The structural features of the U box
include alpha helices (cylinders), beta strands (arrows), beta turns (TT) and alpha turns (TTT). Sequence alignment demonstrates the evolutionary conservation of the
T246 in the U box domain of the CHIP protein across the indicated species. Conservation of residues are labeled as fully conserved (∗), strongly similar (:) or non-
similar (). (B) COS-7 cells were co-transfected with the indicated vectors (transgenes, CTL ¼ pcDNA3, WT ¼ pcDNA3-CHIP, T246M ¼ pcDNA3-CHIP-T246M)
in addition to HA-tagged ubiquitin. HSP70 was immunoprecipitated (IP) with FLAG beads and the resulting precipitants and inputs were immunoblotted (IB) with the
indicated antibodies. (C) COS-7 cells were co-transfected with the indicated transgenes in addition to HA-tagged ubiquitin and immunoprecipitated with either an
HSC70 antibody or rat IgG. The inputs and resulting precipitants (IP) were immunoblotted with the indicated antibodies. Approximate molecular weights in kDa are
also provided. (D and E) Cell-free ubiquitination reactions containing recombinant HSC70 and the indicated CHIP proteins resolved via SDS–PAGE and immuno-
blotted for an antibody recognizing HSC70 (D) or CHIP (E). Ubiquitin (Ub) was excluded in Lane 1 (E) to demonstrate the autoubiquitination of CHIP, arrows indicate
the incomplete reduction of CHIP oligomers.
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suggest that the CHIP-T246M mutation is, at minimum, a partial
loss-of-function mutation, which results in an inability of the
mutantprotein topolyubiquitinatebothchaperone-boundproteins
and the chaperone proteins themselves, functions that are integral
to CHIP’s role in protein quality control (26, 28).
CHIP-deficient mice exhibit defects in motoric, sensory,
cognitive and reproductive function
The profound cerebellar ataxia exhibited by both siblings homo-
zygous for the CHIP-T246M substitution suggests that CHIP
plays a critical role in maintaining cerebellar function. Given
the autosomal recessive nature of CHIP deficiency in our GHS
subjects, we first wanted to assess the neurological behavior of
Chip – /2 mice to determine if the loss of CHIP expression
leads to impairments associated with cerebellar ataxia. Our
group has previously described a line of mice deficient in
CHIP expression (29, 30). Given the data above linking the
human CHIP-T246M mutation with cognitive impairments,
we evaluated the phenotype of Chip2/2 mice using a battery
of behavioral assessments (Supplementary Material,
Fig. S1A). The rotarod test is extensively used in mouse
models to detect cerebellar dysfunction by testing motor coord-
ination and motor learning on a rotating dowel. The performance
of Chip2/2 mice on the rotarod demonstrated a severe motoric
impairment irrespective of gender, with wild-type mice having
between 2.9+ 0.6- and 4.2+ 1.8-fold increase in latency to
falling times in male and female mice, respectively, compared
with Chip2/2 mice (Fig. 4A). The performance of Chip2/2
mice did not improve with retesting (Fig. 4A), demonstrating a
lack of motor learning. To further confirm a motoric defect
and to test for defects in sensory gating, we measured the acous-
tic startle response in wild-type and Chip2/2 mice (Fig. 4B).
Consistent with the motoric impairment observed in Chip2/2
mice using the rotarod assessment, the magnitude of the startle
response was reduced 86% in Chip2/2 mice compared to wild-
type mice (Fig. 4C). Additionally, the reaction time to the acous-
tic startle was delayed across all sound levels by an average of
40%+ 4% (7.8 ms) in Chip2/2 mice (Fig. 4D), consistent
with our hypothesis that the loss of CHIP expression results in
motoric impairment due to cerebellar dysfunction. Interestingly,
prepulse inhibition levels were not affected by the loss in CHIP
expression (Supplementary Material, Fig. S1B), suggesting that
sensory gating (as well as auditory function) was not impaired. In
addition to the deficits attributed to cerebellar dysfunction,
Chip2/2 mice also exhibited an aberrant pattern of exploration
in a novel environment demonstrated by increased time in the
open arms of the elevated plus maze (EPM; Fig. 4E) and a
higher error rate in the acquisition of a spatial learning task in
the Barnes maze (Fig. 4F) compared with wild-type mice, sug-
gesting that hippocampal function may also be impaired with
the loss of CHIP function. Additional testing found no differ-
ences in physical activity, both in the EPM and open field (Sup-
plementary Material, Fig. S1C–E), latency measurers in a
spatial task (Supplementary Material, Fig. S1F) or in social be-
havior (Supplementary Material, Fig. S1F). In gait testing,
Chip2/2 mice took smaller steps relative to wild-type mice
(8–16% reduction in stride length, F(1,16) ¼ 5.515, P ¼
0.032); however, there were no differences in overlap, front
paw stride length or front paw and hind paw base width (data
not shown), suggesting that motoric synchrony is not altered.
Taken together, the loss of CHIP expression appears to have a se-
lective impact in motoric, sensory and cognitive function, in par-
ticular with tasks attributed to cerebellar function.
CHIP expression in the human cerebellum and the
neuropathological and reproductive phenotype of
Chip2/2 mice
In the healthy human brain, CHIP is widely expressed through-
out, including the molecular and granular region of the cerebel-
lum where it is abundantly expressed in Purkinje cells (Fig. 5A).
A similar pattern of CHIP immunoreactivity is found in mouse
brains (31). Histological examination of sagittal cerebellar sec-
tions from Chip2/2 mice revealed cellular loss throughout the
various lobes of the cerebellum, specifically in the Purkinje
cell layer with noticeable degeneration and a 3-fold increase in
the number of pyknotic nuclei compared with an intact Purkinje
cell layer in wild-type cerebellum (Fig. 5B and Supplementary
Material, Fig. S3A), mimicking the observation of Purkinje
cell loss identified in the neuropathological analysis in a
deceased GHS patient with disordered ubiquitination (RNF216
and OTUD4 mutations) (2). The effect on Purkinje cell path-
ology was confirmed with the Purkinje cell-specific marker, cal-
bindin (Fig. 5C, middle). Additionally, calbindin staining
revealed a mosaic expression pattern in Chip2/2 mice where
calbindin expression in the molecular layer is reduced or
absent in regions with significant Purkinje cell loss (Fig. 3C,
left) similar to other mouse models of cerebellar ataxia (32).
Likewise, the cerebellar regions of Chip2/2 mice that do
contain intact Purkinje cells exhibited severe dendritic swelling
(Fig. 3C, right), a common feature in ataxias (33, 34). Taken to-
gether, these data demonstrate that the complete loss of CHIP
function in our mouse model results in behavioral and cellular
phenotypes consistent with the cerebellar ataxia found in
human subjects with the T246M mutation.
The profound lack of sexual development in patients II-1 and
II-2 suggests that CHIP plays a role in neuroendocrine signaling
and is necessary for proper sexual development. Notably, since
originally deriving the Chip2/2 mice (29), we have long been
aware of the inability of Chip2/2 breeding pairs to successfully
mate, necessitating that the Chip2/2 colony be maintained
through Chip+/2 crossings. Not surprisingly, FSH levels in
Chip2/2 mice were reduced .50% when compared with wild-
type littermate mice, irrespective of gender (Fig. 6A), consistent
with the low levels of FSH in patients II-1 and II-2 (Table 1). As
an additional measure of gonadal dysfunction in Chip2/2 mice,
we measured testicular weight and observed a 38% decrease in
Chip2/2 testes compared with wild-type testes (Fig. 6B). Not
surprisingly, CHIP is expressed in wild-type mouse testes as
well as in both male and female human gonads (Supplementary
Material, Fig. S3B and C). Therefore, the Chip2/2 mice also
appear to encompass some of the neuroendocrine deficiencies
seen in patients II-1 and II-2 with the CHIP T246M mutation.
In summary, given the likeness of the neurological and neuroen-
docrine phenotypes in the Chip2/2 mice with those reported in
the GHS patients described in this study, it is highly probably that
the c.737CT in the STUB1 gene results in a loss of CHIP func-
tion in these patients and directly contributes to the disease
phenotype observed in this pedigree.
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DISCUSSION
There is considerable heterogeneity in terms of age of onset and
progression of symptoms within groups of clinical syndromes
presenting with both ataxia and hypogonadism (35). Previous
studies have found mutations in POLR3A and GBA2 associated
with both ataxia and hypogonadism (36, 37), but given the add-
itional complex clinical features in these patients, they were not
diagnosed with GHS. More recently, disordered ubiquitination
was proposed as a contributing factor to the etiology of GHS,
demonstrated by the identification of mutations in the E3
ligase RNF216 and deubiquitinase OTUD4 associated with
GHS in non-Asian populations (2). Consistent with an integral
role for ubiquitination in GHS pathophysiology, in this study,
we identified a mutation in the STUB1 gene encoding the E3
ligase CHIP (Fig. 2A and C) that results in a GHS phenotype
(Fig. 1A and B). Although both hypo- and hypergonadotropic
forms of GHS have been reported, most GHS patients, including
the RNF216-associated GHS patients, usually present with
hypogonadotropic-induced hypogonadism (2, 11). In our
patients, the level of gonadotropin is low given their age, but is
in the normal range for prepubescent individuals; this may indi-
cate a more mild abnormality in the reproductive–endocrine
axis, although the lack of sexual development remains remark-
able. Outside of the fundamental phenotype of GHS, ataxia
and hypogonadism, there are some other distinct differences in
the clinical features of our patients to those harboring RNF216
and OTUD4 mutations; most notably, we did not observe demen-
tia or white matter lesions described previously (2). However, as
mild cognitive impairment was observed in our patients
(Table 1) and likewise in Chip2/2 mice (Fig. 4), we speculate
that cognitive impairment may also act as a core clinical
feature in the STUB1-associated GHS patients. Long-term
Figure4. Chip2/2 mice have extremeataxia and other selective motoric and cognitive impairments. (A) Latency to fall from an accelerating rotarod represented by the
mean+SEM for either Chip2/2 or wild-type mice (n ¼ 5 per genotype per gender). The first three trials were given on the first day of rotarod testing. Retest (R)
indicates the highest latency across two trials given 48 h after the day one trials: ∗∗P , 0.01 comparing Chip2/2 versus wild-type mice at the retest; †P , 0.05
and ††P , 0.01 comparing the indicated time point with first trial within the genotype. (B) The acoustic startle response comprises a prepulse followed by an acoustic
stimulus (AS, 120 dB). Both the reaction time to the AS and the magnitude of the response were measured. (C and D) Amplitude and reaction time of the startle re-
sponse following AS are represented by the mean+SEM for each genotype (n ¼ 6 and 10 for Chip2/2 and wild-type mice, respectively). Trials included no stimulus
trials (No) and AS alone trials: P , 0.05 comparing Chip2/2 versus wild-type mice across all stimulus conditions shown in (C) or as indicated by ∗ in (D). (E and F)
Timeon the open and closed armsof an EPM(E)and the numberof errors (incorrect holes explored)before finding the target holeon the Barnesmaze (F) represented by
the mean+SEM for each genotype (n ¼ 10): ∗P , 0.05 comparing Chip2/2 versus wild-type mice.
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follow-up of the patients will be needed to clarify this issue. Our
finding suggests that patients presenting with GHS without
RNF216 or OTUD4 mutations (2) are also negative for any muta-
tions in the STUB1 gene and that other undiscovered genetic con-
tributors of GHS remain to be elucidated.
It is intriguing that deficiency in either RNF213 or CHIP can
both lead to a similar clinical syndrome. One possible explan-
ation is RNF213 and CHIP ubiquitin ligase substrates converge
to a shared pathway that contributes to GHS. For example, CHIP
could promote ubiquitination and subsequent degradation of
TRAF2, thereby inhibiting the nuclear localization and tran-
scriptional activity of NF-kB (38). RNF216 is also an inhibitor
of TNF and IL-1-induced NF-kB activation and can also act as
a key negative regulator of sustained 2DL4-mediated NF-kB
signaling (39, 40). Thus, dysregulation of the NF-kB pathway
caused by either RNF213 or CHIP deficiencies is a potential
Figure 5. CHIP expression in human cerebellum and the loss of Purkinje cells in Chip2/2 mice. (A) Immunohistochemistry of CHIP expression in adult human cere-
bellum from a healthy female (C) and male (F) with the major regions of the cerebellum identified: molecular layer (ML), Purkinje cell layer (PL) and the granular
layer (GL). The colored arrows highlight intense CHIP immunoreactivity throughout the cerebellum including increased reactivity in Purkinje cells, both in the cell
body (downward arrows) and dendrites (upward arrows). Scale bar represents 100 mm. (B) Representative whole cerebellar sagittal sections from wild-type and
Chip2/2 cerebellums (left) with the major regions labeled at higher power (middle) as shown in (A) stained with either hematoxylin and eosin (left, middle) or
cresyl violet (right). The open arrows identify normal Purkinje cells in wild-type mice, whereas the closed arrows identify the pyknotic nuclei in Purkinje cells in
Chip2/2 cerebellums. (C) Representative whole cerebellar sagittal sections from wild-type and Chip2/2 cerebellums immunostained for calbindin (left).
Magenta arrowheads (left) indicate regions with no calbindin immunoreactivity and the black and red boxes correspond to the higher power images (middle and
right, respectively). The closed arrows identify the pyknotic nuclei present in Purkinje cells (middle) and the cyan arrows identify swollen dendrites in Chip2/2 cere-
bellums. (B and C) Scale bars for whole cerebellum and higher power images are 1 mM and 100mm, respectively.
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common disease-causing factor for GHS. Alternatively,
RNF213 may have some physiological functions that overlap
with the functions of CHIP. Previous studies have demonstrated
that the loss of CHIP expression results in increased accumula-
tion of misfolded proteins and eventual cell death, whereas
over expression of CHIP can be protective in models of
chronic neurodegenerative diseases, including Parkinson’s and
Alzheimer’s disease (7–9, 28, 41). Given the observed neurode-
generation including ataxia and dementia in patients harboring
RNF213 mutations, loss of the E3 ligase activity of RNF213
may also be associated with protein misfolding and aggregation
in neurodegenerative disorders, although more evidence is
needed to support this hypothesis.
Our molecular characterization of the STUB1 c.737CT,
p.Thr246Met mutation demonstrates a loss in ubiquitin ligase
activity (Fig. 3D and E), while still maintaining chaperone inter-
actions (Fig. 3B and C). The ability of CHIP-T246M to maintain
its chaperone interaction without a functional U box may result
in a dominant-negative phenotype versus a complete loss of
CHIP function. Generation of a CHIP-T246M knock-in mouse
and comparison of the pathophysiology related to GHS pheno-
types will provide valuable insight into the role of CHIP in this
disease.Nonetheless,Chip2/2 miceshareseveral strikingphysio-
logical similarities toGHS patients withataxia and hypogonadism
(Fig. 1), including neuronal degeneration (Fig. 5B and C),
pronounced ataxic motor behavior (Fig. 4) and reproductive
impairments (Fig. 6). This strong similarity between the findings
in our GHS patients and those in the Chip2/2 mouse model estab-
lishes an important role for CHIP in the maintenance of cerebellar
function and the reproductive–endocrine axis. Taken together,
our results demonstrate that deficiency of the ubiquitin ligase
CHIP causes ataxia with hypogonadism and further highlight
the role of aberrant ubiquitin ligase function in the pathogenesis
of GHS.
MATERIALS AND METHODS
Exome sequencing and candidate gene validation
Targeted exon enrichment was performed with the use of the
NimbleGen SeqCap EZ Human Exome Library (Roche—Nim-
bleGen Inc.). The exon-enriched DNA libraries were subjected
to paired-end sequencing with the Illumina Hiseq2000 platform
(Illumina). Sequence data were mapped with SOAP2 (42) and
BWA (43) onto the hg18 human genome as a reference. We gen-
erated an average of 15 Gb of sequence with 90× average cover-
age for each individual as single-end, 80-bp reads, calls with
variant quality ,20 were filtered out and 99% of the targeted
bases were covered sufficiently to pass our thresholds for
calling SNPs and small indels (Beijing Genomic Institute, Shen-
zhen, China). Furthermore, coding regions of the STUB1,
RNF213 and OTUD4 gene were amplified by polymerase
chain reaction (PCR) for conventional direct sequencing. Puri-
fied PCR products were sequenced on an ABI 3500 Genetic
Analyzer (Life Technologies, Carlsbad, CA, USA). Sanger
sequencing results were analyzed by Mutation Surveyor (Soft-
genetics, State College, PA, USA) and reconfirmed by the
same procedure.
Expression plasmids and recombinant proteins
Mammalian expression plasmids pcDNA3-myc-CHIP, pcDNA3-
myc-CHIP-K30A, pcDNA3-myc-CHIP-H260Q, HA-Ubiquitin
and FLAG-HSP70 were used as described previously (5, 26, 44).
CHIP, CHIP-H260Q, CHIP-K30A, CHIP-T246M and HSC70
recombinant proteins were produced in Escherichia coli
BL21(DE3) as His-tagged fusion proteins by induction with
0.1 mM isopropyl-1-thio-b-D-galactopyranoside overnight at
188C followed by purification with HisTrapTM HP columns
(GE Healthcare), concentrated, and stored in in 20 mM HEPES
(pH 7.4) with 150 mM NaCl.
Mutagenesis
A point mutation of threonine to methionine at position 246 of
CHIP was created by site-directed mutagenesis using the Q5 Site-
Directed Mutagenesis Kit (New England Biolabs, E0554S)
according to manufacturer’s instructions using previously des-
cribed pcDNA3-myc-CHIP template (5) and mutagenic primers
5′-CCGTGCATCATGCCCAGTGGC-3′ and 5′-CTCCCGCA
TCAGCTCAAAGC-3′ (BaseChanger software, New England
Biolabs). The myc-CHIP-T246 expression plasmid was produced
by transformation in E. coli DH5a, purified and the single-base
pair substitution was verified by DNA sequencing.
Figure 6. Hypogonadism in Chip2/2 mice. (A) Serum levels of FSH in wild-type
and Chip2/2 mice represented by the mean+SEM for each genotype (n ¼ 10):
∗P , 0.05; ∗∗P , 0.01 comparing Chip2/2 versus wild-type mice. (B) Repre-
sentative pictographs of testes and testicle weights from wild-type and
Chip2/2 mice. Scale bar represents 20 mM. Weights are represented in mg of tes-
ticle per mm of tibia length to control for animal size and represented by the
mean+SEM for each genotype (n ¼ 10 and 8, wild-type and Chip2/2 mice, re-
spectively).
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In vitro ubiquitination reactions
In vitro ubiquitination reactions were carried out as previously
described (5). Briefly, 0.75 mg (1 mM) of bacterially expressed
HSC70 was incubated in the presence of 2.5 mM CHIP or
CHIP mutants, 50 nM purified Ube1 (BostonBiochem, E305),
2.5 mM purified UbcH5c (BostonBiochem, E2–627) and
0.25 mM ubiquitin (BostonBiochem, U100H) in 50 mM Tris
(pH 7.5), 600 mM DTT, 2.5 mM MgCl2-ATP (BostonBiochem,
B20) in a total volume of 10 ml for 1 h at 378C. Samples were
analyzed by 4–12% Bis–Tris SDS–PAGE and immunoblotting
was performed with either anti-HSC70 (Enzo, ADI-SPA-815) or
anti-CHIP (Sigma, S1073) antibodies.
Cell culture and transfection
COS-7 cells were maintained in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal bovine
serum (Sigma) at 378C inan atmosphereof5%CO2. Cell transfec-
tions were performed using X-tremeGENE 9 (Roche) with the
indicated plasmid DNA at a 1:3 DNA to X-tremeGENE 9 ratio.
Immunoprecipitation/co-immunoprecipitation of
FLAG-HSP70/CHIP from COS-7 cells
1E6 COS-7 cells were plated in normal growth media in 10 cm2
tissue culture-treated dishes and incubated overnight under
normal growth conditions. Cells were then transiently trans-
fected with pcDNA3-mycCHIP (0.5 mg), pcDNA3-mycCHIP
T246M (2.5 mg), pcDNA3 (2.5 mg) and/or FLAG-HSP-70
(2 mg) and HA-Ubiquitin (1 mg) and incubated for 24 h under
normal growth conditions, followed by treatment with 20 mM
MG132 or DMSO for 2.5 h prior to harvest. Cells were washed
in cold PBS and lysed in Cell Lytic M (Sigma) containing 1×
HALT protease/phosphatase inhibitor (Pierce) and 50 mM
PR619 (Lifesensors). Lysates were clarified by centrifugation
at 15 000g for 10 min. Total protein concentration was deter-
mined by BCA protein assay (Pierce) and 1 mg total protein
clarified lysate incubated overnight at 48C with 20 mg of either
EZviewTM Red ANTI-FLAGw M2 or ANTI-HA Affinity Gel
(Sigma). The gel was then washed five times with Tris-buffered
saline with 0.5% Nonident P-40; subsequently, proteins were
eluted in reducing SDS-sample buffer and analyzed by SDS–
PAGE and western blotting was performed using anti-Hsp70
(Enzo ADI-SPA-810), anti-FLAG HRP (Sigma, A8592),
anti-HA HRP (Sigma, A6533) and anti-myc HRP (Sigma,
A5598) antibodies.
Immunoprecipitation/co-immunoprecipitation of
HSC70/CHIP from COS-7 cells
1E6 COS-7 cells were plated in normal growth media in 100 mM
tissue culture-treated dishes and incubated overnight under
normal growth conditions. Cells were then transiently trans-
fected with pcDNA3-mycCHIP (1.5 mg), pcDNA3-mycCHIP
T246M (4 mg) or pcDNA3 (1.5 mg) and HA-Ubiquitin and incu-
bated for 24 h under normal growth conditions, followed by
treatment with 20 mM MG132 or DMSO control for 2.5 h prior
to harvest. Cells were washed 1× in cold PBS and lysed in
Cell Lytic M (Sigma) containing 1× HALT protease/
phosphatase inhibitor (Pierce) and 50 mM PR619 (LifeSensors).
Lysates were clarified by centrifugation at 15 000g for 10 min.
Total protein concentration was determined by BCA protein
assay (Pierce) and 1.8 mg total protein clarified lysates were
incubated overnight at 48C with 10 mg anti-Hsc70 (Enzo
ADI-SPA-815) or rat IgG antibodies. One hundred and twenty
microliters of Protein-G Dynabeads (Invitrogen) were then
added to each sample and incubated for 0.5 h at room tempera-
ture with rotation. Beads were washed four times with
phosphate-buffered saline with 0.05% Tween-20; subsequently,
proteins were eluted in SDS-sample buffer and analyzed by
SDS–PAGE and western blotting using anti-Hsc70 (Enzo
ADI-SPA-815), anti-CHIP (abcam, Ab4448), anti-HA HRP
(Sigma, A6533) and anti-myc HRP (Sigma, A5598) antibodies.
Mouse behavioral assessments
All tests and measures are detailed in the Extended Experimental
Procedures provided in Supplementary Material.
Histology
Mouse brains were carefully excised, gently rinsed, fixed in 4%
paraformaldehyde for 24 h and then placed in 70% ethanol prior
to embedding into paraffin. Five micrometer sections were pro-
cessed for histology, and stained with either hematoxylin and
eosin or cresyl violet for routine histological examination. Un-
stained sections were used to detect calbindin expression using
immunohistochemistry. Slides were stained per the manufactur-
er instructions using the calbindin D1I4Q rabbit monoclonal
antibody (Cell Signaling, 13176) with citrate antigen retrieval,
SignalStainw Boost Detection Reagent (Cell Signaling, 8114),
and SignalStainw DAB Substate Kit (Cell Signaling, 8059). De-
generating neurons were characterized via light microscopic
level by cell body shrinkage, loss of Nissl substance and a
small/shrunken darkly stained (pyknotic) nucleus as described
(45). Human cerebellum, testes and ovary sections were from
the Human Protein Atlas tissue array (46) and were stained
with anti-CHIP antibody (Sigma, C9243).
Statistical analyses
For the mouse behavioral studies and hormone levels, data were
analyzed using two-way ANOVA looking for effects of geno-
type or sex, or when applicable, repeated measures ANOVAs.
Fisher’s protected least-significant difference tests were used
for comparing group means only when a significant F-value
was determined. For all other analyses, unpaired data sets were
analyzed using a two-tailed Student’s t-test with P-values of
,0.05 considered significant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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